Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Date:12/13/2011

CAMBRIDGE, Mass., Dec. 13, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a fully human monoclonal antibody that targets ErbB3, with cetuximab (Erbitux®) and irinotecan (Camptosar®) in patients with advanced cancers.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 1 study evaluates the safety and pharmacokinetics of MM-121 when administered in combination with cetuximab and irinotecan in patients with advanced colorectal cancer, squamous cell head and neck cancer, non-small cell lung cancer, triple negative breast cancer, or other types of solid tumors that depend on epidermal growth factor receptor (EGFR) activity. Multiple centers across the United States are expected to participate in this study. The first patient was enrolled at the Huntsman Cancer Institute at the University of Utah in Salt Lake City.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communicat
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
4. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Synthetic Biologics, Inc. (NYSE ... drug candidates targeting specific pathogens that cause serious infections ... unusual market activity in the Company,s stock, the NYSE ... with its usual practice. The Company stated that its ... About Synthetic Biologics, Inc. Synthetic ...
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... YORK , July 29, 2014  Longtime industry ... Caremark Rx, Drew Crawford today announced the ... the leading independent media source dedicated to delivering fair, ... on the pharmacy benefit management (PBM) industry .  ... of, and context behind, industry news.   The outlet will ...
Breaking Medicine Technology:Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3Drew Crawford Announces Launch of PBM365 Media 2
(Date:7/30/2014)... Computer Resources of America, Inc. (CRA), an ... City, has been awarded the contract to rewire the ... large global bank. The bank is a global leader ... of CRA said, “Being awarded this contract with our ... what has already been a successful and deep relationship. ...
(Date:7/30/2014)... According to the Critical Bench Program 2.0 Pdf review ... for men who want to discover how to increase their ... within a few months. Inside this book, learners will discover ... and avoid the aches and pains. , Vkool reveals in ... learners the reason why stretching and warming up is so ...
(Date:7/30/2014)... 30, 2014 pMD, the leading ... launched an Observation Result (ORU) interface to streamline ... cardiology customers are using the ORU interface to ... test interpretations for electrocardiograms, echocardiograms, and stress tests. ... hospital, the cardiology system produces electronic data for ...
(Date:7/29/2014)... VisitandCare.com today announced that several ... the company’s exclusive network to help couples struggling with ... — as top fertility clinics in Spain, Switzerland, Greece, ... and successful IVF treatments. , The exclusive selection of ... by professionals at VisitandCare.com. The goal is to connect ...
(Date:7/29/2014)... 2014 Phytceramides are a natural anti-aging tool for ... new book. , Today is the last day to nab a ... Best . The book is also sold in hard copy. , ... that Phytoceramides were so new and very unknown in ... book now," says Kathy Heshelow, founder of Sublime Beauty®. "It is ...
Breaking Medicine News(10 mins):Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3
... Services, Treatment and Prevention Available--MINNEAPOLIS, April 29 ... health care centers in the United States, is ... flu (H1N1) and provide rapid testing services, treatment ... medically appropriate. MinuteClinic is coordinating with local ...
... 29 Grupo Aeroportuario del Sureste, S.A.B. de C.V. ... first privatized airport group in Mexico and operator of Cancun ... today that on April 26, 2009 the Mexican Secretary of ... in Mexico. On April 28, 2009 the World Health Organization ...
... BOTHELL, Wash., April 29 SCOLR Pharma, Inc. (NYSE Alternext ... financial results on Friday, May 1, 2009, at 8:30 a.m. ... Pharma, will host the conference call at 11:30 a.m. Eastern, ... other interested parties may participate in the conference call by ...
... Survey finds many cities have dangerously high levels of pollution ... of the nation,s population, 186.1 million people to be exact, ... air pollution, new research shows. , "Six out of ten ... the emergency room, to shape how kids, lungs develop and ...
... 2009 Relationships are difficult and most of us probably ... when discussing stressful issues, like home finances, is an impossible ... take the "edge" off these discussions? The biology of ... research on social cognition conducted in animals is now informing ...
... Michigan physicians are the first in the nation ... through a new partnership announced today by the American ... with Compuware,s Covisint subsidiary. This partnership builds on ... the AMA announced its agreement with Covisint to develop ...
Cached Medicine News:Health News:MinuteClinic is Educating Consumers About Swine Flu 2Health News:MinuteClinic is Educating Consumers About Swine Flu 3Health News:SCOLR Pharma, Inc. Schedules First Quarter 2009 Financial Results Conference Call for May 1, 2009 at 11:30 A.M. Eastern 2Health News:More Than Half of Americans Living with Dirty Air 2Health News:More Than Half of Americans Living with Dirty Air 3Health News:Oxytocin: Love potion #1? 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
... qualitative differential detection of ... and an antigen that is ... of malaria:plasmodium falciparum (P.f), plasmodium ... and Plasmodium malariae (P.m) in ...
Medicine Products: